1-3 of 3
Whitney Stewart, BS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Catherine C Smith, MD, Kimberly Lin, BS, Elisabeth Lasater, PhD, Whitney Stewart, BS, Lauren E Damon, Andrew Kasarskis, PhD, Ali Bashir, PhD, Matthew Pendleton, Robert Sebra, Alexander E Perl, MD, Mai H Le, MD, Chao Zhang, PhD, Brian West, Ph.D., Neil P. Shah, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3938.
https://doi.org/10.1182/blood.V122.21.3938.3938
Published: 2013
Journal Articles

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Catherine C Smith, MD, Elisabeth Lasater, PhD, Melissa Mccreery, BS, Kimberly Lin, BS, Whitney Stewart, BS, Lauren E Damon, Alexander E Perl, MD, Grace R Jeschke, Mayumi Sugita, MD, Martin Carroll, MD, Scott C. Kogan, MD, Neil Shah, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 141.
https://doi.org/10.1182/blood.V120.21.141.141
Published: 2012
Journal Articles

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Catherine C Smith, MD, Jason Chin, PhD, Elisabeth Lasater, PhD, Amy L. Paguirigan, PhD, Kimberly Lin, BS, Whitney Stewart, BS, Sara Salerno, BS, Lauren E Damon, Mark J. Levis, MD, PhD, Alexander E Perl, MD, Kevin Travers, PhD, Andrew Kasarskis, PhD, Jerald P. Radich, MD, Neil Shah, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 674.
https://doi.org/10.1182/blood.V120.21.674.674
Published: 2012